Skip to main content
Clinical Trials/NCT07307898
NCT07307898
Active, not recruiting
Not Applicable

Cavitation Versus Whole-Body Electromyostimulation on Infilamatory Markers in Centeral Obesity

Cairo University1 site in 1 country60 target enrollmentStarted: September 5, 2024Last updated:

Overview

Phase
Not Applicable
Status
Active, not recruiting
Enrollment
60
Locations
1
Primary Endpoint
Inflammatory Markers

Overview

Brief Summary

The purpose of this study is to compare the effects of ultrasound cavitation and whole-body electromyostimulation (WB-EMS) on inflammatory markers in individuals with central obesity.

Detailed Description

Sixty individuals with central obesity were recruited from private clinics. And underwent a screening process to determine their eligibility based on the inclusion and exclusion criteria. Eligible participants were informed about the study details, procedures, potential risks, and benefits before obtaining written informed consent

Study Design

Study Type
Interventional
Allocation
Randomized
Intervention Model
Parallel
Primary Purpose
Treatment
Masking
Double (Participant, Outcomes Assessor)

Eligibility Criteria

Ages
18 Years to 50 Years (Adult)
Sex
All
Accepts Healthy Volunteers
Yes

Inclusion Criteria

  • Adults aged 18-50 years.
  • Individuals diagnosed with central obesity, defined as a waist circumference greater than 102 cm in men and 88 cm in women.
  • Participants with a stable body weight for at least three months prior to the study.
  • No engagement in regular physical activity or weight loss programs in the past six months.
  • Willingness to adhere to study protocols and attend all scheduled sessions.

Exclusion Criteria

  • Individuals with chronic diseases other than obesity-related conditions, such as cardiovascular disease, diabetes, or severe hypertension.
  • Pregnant or lactating women.
  • Individuals with implanted electronic devices (e.g., pacemakers).
  • Participants with dermatological conditions or skin infections in the treatment area.
  • Individuals undergoing medication that may affect fat metabolism or inflammatory markers.

Outcomes

Primary Outcomes

Inflammatory Markers

Time Frame: 3 Monthes

Measurement of changes in levels of Tumor Necrosis Factor-alpha (TNF-alpha), and Interleukin-6 (IL-6) using ELISA (Enzyme-Linked Immunosorbent Assay) kits.

Secondary Outcomes

  • Waist Circumference(3 Monthes)
  • Body Weight(3 Monthes)
  • Body Mass Index (BMI)(3 Monthes)

Investigators

Sponsor Class
Other
Responsible Party
Principal Investigator
Principal Investigator

Hadeer Elsayed Abdelrazik Elsayed Ramadan

physical therapist

Cairo University

Study Sites (1)

Loading locations...

Similar Trials